Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases

Bewersdorf, Jan Philipp; Parmar, Nishita; Israel, Gary M.; Gettinger, Scott; Lee, Alfred Ian

doi:10.1007/s11239-021-02428-0

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All reported patients survived to discharge, with the exception of one patient who had cardiogenic emboli to multiple sites. Bewersdorf et al ( 7 ) conducted a large cohort study of SI in 206 cancer patients. The authors mentioned that there was no statistically significant difference in the risk of subsequent venous thromboembolism and recurrent SI among patients with or without anticoagulant therapy.…”

Section: Discussionmentioning

confidence: 99%

“…However, patients taking anticoagulants pose a higher bleeding risk, and the management of bleeding complications in patients under anticoagulant therapy is challenging ( 6 ). Previous studies demonstrated that 30% to 100% of patients with SI received anticoagulant therapy ( 1 , 3 , 7 ). To date, no studies have directly compared patients who initiated anticoagulants to those without treatment in the future risk of thromboembolic events and long-term overall survival.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anticoagulant Therapy Is Associated With Decreased Long-Term Mortality in Splenic Infarction Patients: A Multicenter Study

et al. 2021

View full text Add to dashboard Cite

Background: Patients with splenic infarction (SI) are associated with a prothrombotic state and are vulnerable to subsequent thromboembolic complications. However, due to its rarity, there is no established treatment modality in this population. We aimed to examine the effect of anticoagulant therapy in SI patients.Methods: We performed a multicenter retrospective cohort study of 86 SI patients. Patients were categorized as anticoagulant users and anticoagulant non-users. The associations between anticoagulant therapy, all-cause mortality, thromboembolic events and bleeding events were evaluated.Results: Forty-five patients (52.3%) received anticoagulant therapy during the follow-up periods. The all-cause mortality rate was 6.86 per 100 patient-years. Anticoagulant therapy was associated with 94% improved survival (HR = 0.06; Cl 0.007–0.48; p = 0.008), while the risk factors for all-cause mortality were prior stroke (HR = 13.15; Cl 2.39–72.27; p = 0.003) and liver cirrhosis (HR = 8.71; Cl 1.29–59.01; p = 0.027). Patients with anticoagulant therapy had a higher event-free survival curve for thromboembolic complications (p = 0.03) but did not achieve a significant difference after adjustment using the Cox regression model as a time-dependent covariate (HR = 0.57; Cl 0.13–2.45; p = 0.446). There was no significant difference in the risk of bleeding events between the groups (p = 0.728).Conclusions: Anticoagulant therapy in patients with SI was associated with better survival and was not related to an increased bleeding risk.

show abstract

Section: Discussionmentioning

confidence: 99%